GCM
DRUG

Ghisallo Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

Ghisallo Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,000
Closed -$803K – 343
2026
Q1 		$803K Buy
+11,000
New +$885K 0.02% 242

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ghisallo Capital Management's DRUG Position: Q2 2026 in Review

Ghisallo Capital Management sold out of Bright Minds Biosciences (DRUG) in Q2 2026, closing a stake of 11,000 shares — an estimated $803K sold.

Ghisallo Capital Management first reported a position in DRUG in Q1 2026 and held it in 1 quarter. The position peaked at $803K in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Ghisallo Capital Management reported no remaining Bright Minds Biosciences position as of Q2 2026 after selling out during the quarter.
  • Ghisallo Capital Management sold 11,000 Bright Minds Biosciences shares in Q2 2026, an estimated $803K.
  • Ghisallo Capital Management first reported a position in Bright Minds Biosciences in Q1 2026 and held it in 1 quarter.
  • Ghisallo Capital Management's Bright Minds Biosciences position peaked at $803K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.